Scholar Rock (NASDAQ:SRRK) Director Katie Peng Sells 1,006 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $44.09, for a total transaction of $44,354.54. Following the completion of the sale, the director owned 32,908 shares of the company’s stock, valued at $1,450,913.72. This represents a 2.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Scholar Rock Stock Down 2.5%

Shares of Scholar Rock stock opened at $42.93 on Friday. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $48.28. The company has a market cap of $4.38 billion, a price-to-earnings ratio of -13.63 and a beta of 0.61. The company’s 50 day moving average is $36.36 and its 200 day moving average is $35.39.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter last year, the firm posted ($0.66) EPS. Research analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Hedge Funds Weigh In On Scholar Rock

Hedge funds have recently modified their holdings of the company. Northern Trust Corp raised its position in shares of Scholar Rock by 2.5% during the 1st quarter. Northern Trust Corp now owns 765,280 shares of the company’s stock valued at $24,604,000 after purchasing an additional 18,753 shares during the period. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. increased its stake in Scholar Rock by 145.3% in the 2nd quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock worth $27,254,000 after buying an additional 455,753 shares in the last quarter. Intech Investment Management LLC raised its holdings in Scholar Rock by 60.9% during the first quarter. Intech Investment Management LLC now owns 56,784 shares of the company’s stock valued at $1,826,000 after acquiring an additional 21,483 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Scholar Rock during the first quarter valued at about $458,000. Finally, Nuveen LLC purchased a new position in shares of Scholar Rock in the first quarter valued at about $12,775,000. 91.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SRRK has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Wednesday, October 8th. Truist Financial decreased their price target on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, October 20th. Wolfe Research initiated coverage on shares of Scholar Rock in a research note on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target on the stock. Finally, HC Wainwright reduced their price objective on Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Four equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $48.92.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.